.jetcityimage/iStock Content via Getty Images Morgan Stanley has actually opted for Eli Lilly (NYSE: LLY) as its own top biopharma selection for 2025 as well as rated another 9 labels in the area as obese. The investment banking company said in a note that it continues to strongly believe “diabesity is set to end up being.